Início › Insuficiência Cardíaca › Missouri › St. Louis
Ensaios clínicos de Insuficiência Cardíaca em St. Louis, MO
26 estudos para Insuficiência Cardíaca estão buscando participantes em locais em St. Louis e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RecrutandoFase 3
- St. Louis Heart and Vascular, P.C., St Louis
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
RecrutandoFase 3
- St. Louis Heart and Vascular, P.C., St Louis
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
RecrutandoFase 2
- Washington University School of Medicine, St Louis
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
RecrutandoFase 3
- Research Site, Bridgeton · a 15 mi de distância
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RecrutandoFase 3
- Washington University Center for Advanced Medicine, St Louis
A Study of LY3971297 in Participants With Heart Failure
RecrutandoFase 1
- Washington University, St Louis
Alleviant ALLAY-HFrEF Study
Recrutando
- Washington University - St Louis, St Louis
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
RecrutandoFase 3
- Research Site, St Louis
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
Recrutando
- WashU Medicine, St Louis
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
RecrutandoFase 2
- Local Institution - 109, St Louis
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
RecrutandoFase 2/3
- Washington University-Pediatric Cardiology/ St. Louis Children's Hospital ( Site 0006), St Louis
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
RecrutandoFase 2
- Washington University Center for Advanced Medicine, St Louis
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
RecrutandoEstudo observacional
- St Louis, St Louis
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
RecrutandoEstudo observacional
- Washington University, St Louis
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
RecrutandoFase 3
- Tenax Investigational Site, St Louis
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
RecrutandoFase 3
- Washington University, St Louis
- Amicis Centers of Clinical Research, St Louis
Alleviant ALLAY-HF Study
Recrutando
- Washington University - St Louis, St Louis
Assessment of CCM in HF With Higher Ejection Fraction
Recrutando
- St. Louis Heart and Vascular, Bridgeton · a 15 mi de distância
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
RecrutandoFase 3
- Washington Univ School Of Medicine, St Louis
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
RecrutandoFase 3
- Washington University - St. Louis Children's Hospital - Cardiology, St Louis
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
RecrutandoFase 3
- Washington University - St. Louis Children's Hospital - Cardiology, St Louis
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
RecrutandoFase 2
- Washington University School of Medicine, St Louis
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Recrutando
- St. Louis Heart and Vascular, St Louis
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
RecrutandoFase 3
- Washington University, St Louis
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
Recrutando
- Washington University - Barnes Jewish Health Hospital, St Louis
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
RecrutandoFase 1/2
- Washington University in Saint Louis, St Louis
Ensaios de Insuficiência Cardíaca em outras cidades
- New York City, NY51 estudos
- Boston, MA44 estudos
- Dallas, TX42 estudos
- Houston, TX36 estudos
- Cleveland, OH33 estudos
- Chicago, IL31 estudos
- Philadelphia, PA31 estudos
- San Francisco, CA29 estudos
- Durham, NC26 estudos
- Atlanta, GA25 estudos
- Kansas City, MO25 estudos
- Baltimore, MD24 estudos
Outros estudos em St. Louis
- Câncer de Pulmão de Não Pequenas Células73 estudos
- Câncer de Mama64 estudos
- Câncer Metastático54 estudos
- Câncer Colorretal50 estudos
- Câncer de Próstata46 estudos
- Câncer (todos os tipos)46 estudos
- Câncer de Pulmão39 estudos
- Câncer de Ovário38 estudos
- Câncer de Pâncreas33 estudos
- Câncer Endometrial29 estudos
- Carcinoma de Células Escamosas de Cabeça e Pescoço28 estudos
- Obesidade25 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.